🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT05007301
Active, not recruiting

Geko™ Cross Therapy Registry - Wound

NCT05007301 · tracked via the Priya Life Science UK tracker
Sponsor
Firstkind Ltd
Phase
Started
2022-04-04
Last updated
2026-09-15

Condition(s) studied

WoundVenous Leg UlcerDiabetic Foot UlcerArterial Leg Ulcer

Investigational drug(s) / intervention(s)

geko device

geko device: Neuromuscular electrostimulation of the peroneal nerve, 12h per day, for up to 12 weeks.

Study summary

The geko™ Cross Therapy REGISTRY - Wound is a prospective, observational, anonymised data collection Registry with no experimental treatment that will fulfil an unmet need for an observational Registry to provide long-term clinical data to demonstrate patient benefit and regulatory compliance.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Aged ≥ 18 years 2. Intact healthy skin at the site of geko™ device application. 3. Willing and able to give written informed consent 4. Presence of an ulcerative wound to the lower leg 5. Identified to receive geko™ therapy as part of their standard care for wound management. Exclusion Criteria: 1. Pregnancy or breast feeding. 2. Use of any other neuro-modulation device. 3. Current use of TENS in the pelvic region, back or legs 4. Trauma to the lower limbs that would prevent geko™ from stimulating the common peroneal nerve. 5. No response to geko™ therapy i.e., no involuntary rhythmic upward and outward movement of the foot (dorsiflexion) at the maximum tolerable device setting

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Northwell Health System New York New York
Central London Community Health Care NHS Trust London United Kingdom
Norfolk Community Health and Care NHS Trust Norwich United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05007301 on ClinicalTrials.gov ↗ ← All trials in the UK